GSK717;1H-Benzimidazole-1-acetamide, 2-[2-(benzoylmethylamino)ethyl]-N-(2,3-dihydro-1H-inden-5-yl)-;N-(2-(1-(2-((2,3-Dihydro-1H-inden-5-yl)amino)-2-oxoethyl)-1H-benzo[d]imidazol-2-yl)ethyl)-N-methylbenzamide;immune,GSK717,inhibit,Inhibitor,NOD2-TLR2,pro-inflammatory,MDP-stimulated,NOD-like Receptor (NLR),responses,cytokines,synergy,GSK 717,GSK-717;GSK717, 10 mM in DMSO;N-(2-(1-(2-((2,3-Dihydro-1H-inden-5-yl)ao)-2-oxoethyl)-1H-benzo[D]imidazol-2-yl)ethyl)-N-methylbenzamide
GSK717 is a potent and selective inhibitor of NOD2 (nucleotide-binding oligomerization domain-containing protein 2); it inhibits MDP (muramyl dipeptide)-induced NOD2-mediated signaling with an IC50 of 400 nM in MDP-stimulated HEK293/hNOD2 cells; it blocks the synergy between NOD2 and TLR2; it does not affect NOD1-, TNFR1-, or TLR2-mediated responses; it inhibits the release of pro-inflammatory cytokines IL-8, IL-6, TNFα, and IL-1β in primary human monocytes stimulated with MDP.